Drugs / LML134
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02334449 | Feb 2015 → Feb 2016 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03141086 | Jul 2017 → Aug 2018 | circadian rhythm sleep disorder, shift work type | Novartis Pharmaceuticals | Terminated | Missed primary Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LML134 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02334449 ↗ |
| Modality | Small molecule | — CHEMBL3700336 ↗ |